Kymera Investor Day Presentation Deck

Mean (± SE) Percent IRAK4 Change from Baseline at 48hr 20 -20 -40 -60 -80 -100 KT-474 Achieved >95% IRAK4 Degradation After Single Dose + Placebo Percent IRAK4 Reduction in PBMC at 48 Hours Post-Dose Using Mass Spectrometry Median IRAK4 Change -2% 25 mg SD 75 mg SD 300 mg SD 150 mg SD |||| KYMERA ©2021 KYMERA THERAPEUTICS, INC. 600 mg SD 1600 mg SD 1000 mg SD N Placebo 13 KYMERA R&D DAY - December 16th, 2021 25 mg 75 mg 150 mg 300 mg 600 mg 1000 mg 1600 mg * p-values relative to placebo 6 6 6 6 7 5 Mean IRAK4 Change 6 -1% -26% -73% -81% -84% -96% -93% -95% -39% -75% -82% -89% -96% -94% -95% p value 0.1 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 PAGE 28

View entire presentation